Oxford BioMedica PLC (OXBDF)

[marcusl2]

HTTPS://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358667/

In Brief
Posey and colleagues developed a CAR T cell therapy to break immune tolerance to solid tumors by targeting an aberrantly glycosylated, cancer-specific glycoprotein in multiple cancer histotypes and demonstrated efficacy and safety in tumors as diverse as leukemia and pancreatic cancer.

Highlights
Cancer cells of many tissues express an abnormal glycoform of MUC1, Tn-MUC1
Normal human tissue does not express detectable Tn-MUC1 on the cellular surface
CAR T cells are engineered to target Tn-MUC1 lyse tumor cells in vitro and in vivo
Abnormal glycoform epitopes are valid clinical targets for CAR T cells